Nanoparticle News and Research

RSS

In nanotechnology, a particle is defined as a small object that behaves as a whole unit in terms of its transport and properties. It is further classified according to size: in terms of diameter, fine particles cover a range between 100 and 2500 nanometers, while ultrafine particles, on the other hand, are sized between 1 and 100 nanometers.

Nanoparticle structural design improves disease biomarker detection sensitivity

A nanoparticle's performance depends on more than what it is made of-it can also depend on how its building blocks are arranged.

3 Nov 2026

Targeting EGFR signaling to reduce mucus overproduction in lung diseases

Airway mucus is part of innate lung defense, but when production overwhelms clearance, it obstructs airflow and worsens disease.

2 Nov 2026

How microplastics and bacteria interact to drive antibiotic resistance

Microplastics can change how bacteria form biofilms and develop antibiotic resistance. Maria Jazmin Silvero Compagnucci explains.

From Pittcon 22 Oct 2026

Targeting mitochondrial vulnerabilities could help treat triple-negative breast cancer

A deeper understanding of mitochondrial function could create new opportunities for treating triple-negative breast cancer (TNBC), one of the most aggressive and difficult-to-treat forms of breast cancer.

12 Oct 2026

Certain gut bacteria may intensify inflammatory responses to vaccines

A person's microbiome may help determine whether they develop a fever after receiving a vaccination, according to a new study.

8 Oct 2026

Highlight Therapeutics presents positive Phase 2b topline results of intralesional BO‑112 in localized basal cell carcinoma as a late-breaker at EADV

Highlight Therapeutics, a clinical‑stage biotechnology company developing immune activators to transform the treatment of skin tumors, today announced positive results from the multicenter, single-arm Phase 2b SPOTLIGHT‑204 clinical trial evaluating BO‑112, a novel dsRNA-based intralesional treatment for patients with resectable primary low‑ and high‑risk basal cell carcinoma (BCC).

1 Oct 2026

New nanoparticles could protect soldiers from deadly nerve agents

Nanoparticles could someday provide a new way to help soldiers fight back against deadly nerve agents on the frontline.

29 Sep 2026

Experimental mRNA therapy protects the liver after acetaminophen overdose

When a patient arrives at the hospital with an acetaminophen overdose, it's often a race against the clock. The only FDA-approved antidote for overdose-related liver injury, N‑acetylcysteine, must be administered within hours to be effective.

28 Sep 2026

MIT engineers use artificial intelligence to create heat-resistant RNA vaccines

MIT engineers have found a way to stabilize the lipid nanoparticles used to deliver RNA vaccines, which could allow the vaccines to be more widely distributed.

28 Sep 2026

Better storage buffers could pave way for safer mRNA therapies

Researchers at The University of Texas at Austin have teamed up with pharmaceutical leader Eli Lilly and Company to uncover new information about mRNA lipid nanoparticles (LNPs), the technology behind COVID-19 vaccines and other important treatments, and how to make it more effective.

25 Sep 2026

Advances in chemistry and delivery are taking oligonucleotide medicines beyond rare diseases

A review in Cell Reports Medicine examines how advances in oligonucleotide chemistry and delivery have established ASOs and RNA interference therapies as a class of genetic medicines, with 21 oligonucleotides approved at the time of writing. It also identifies extrahepatic delivery, safety, target validation, individualized treatment, and data quality as priorities as the field expands into common diseases and explores AI-assisted development.

24 Sep 2026

Insilico Medicine launches AI initiative to develop longevity vaccines

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced Longevity Vaccines, a research initiative developing treatments that direct a patient's own immune cells to eliminate the earliest cellular drivers of age-related disease.

15 Sep 2026

Targeted nanoparticles strengthen anti-cancer immune responses in tumors

Adelaide University researchers have developed a new way of using mRNA technology to reprogram tumor-supporting immune cells and strengthen the body's anti-cancer immune response.

11 Sep 2026

New laser-fabricated plasmonic chip accurately identifies and sorts cancer cells

Novel laser-fabricated plasmonic chip combines 185 nm Raman resolution and deep learning to identify and sort cancer cells with 96.2% accuracy.

9 Sep 2026

Advancing intracellular delivery with LumiPore®: A new approach to cell transfection and drug discovery

Discover how LumiPore improves intracellular delivery with gentle, high-efficiency transfection for drug discovery and cell therapy research.

From Trince 8 Sep 2026

Mosaic nanoparticle vaccine boosts broad mucosal coronavirus immunity

The persistent threat of emerging coronaviruses highlights the critical need to establish frontline defenses directly at the respiratory entry portal.

4 Sep 2026

Nanoparticle flu vaccine design could pave way for broader protection

Influenza viruses constantly shapeshift to evade recognition by the immune system. This shapeshifting occurs in critical proteins like hemagglutinin (HA), which controls how the virus attaches to human cells before entering them.

2 Sep 2026

New method based on human blood simplifies mRNA drug development

mRNA-based drugs are emerging as the drug of the future for a wide range of diseases, but they are difficult and time-consuming to develop.

1 Sep 2026

UMass Amherst researcher wins $2.5 million to expand nanoparticle cancer vaccine study

Having established the effectiveness of her nanoparticle drug-delivery system for cancer immunotherapy, University of Massachusetts Amherst researcher Prabhani Atukorale, has been awarded $2.5 million from the National Institutes of Health to broaden the scope of her vaccine research to include treating those with active cancer.

27 Aug 2026